Getting PrEP into the hands of young people at high risk for HIV infection is a priority that experts are now discussing. A recent webinar and Q&A session hosted by HIVE brought together PrEP providers from across the country to talk about some of these issues and share successes and challenges.
"When you look at who's been left behind in PrEP uptake, there are many communities that haven't had the same access, and youth are certainly one of them," said Adam Leonard, from San Francisco Department of Public Health. "As a city, we're really trying to focus on what youth need to access PrEP."
Truvada is approved as an HIV medication for people 12 and older, but only as PrEP for people 18 and older. This makes it more difficult -- or impossible -- for people who are under 18 to access and use insurance or patient assistance programs to pay for Truvada as PrEP. Compounding those issues are additional concerns about confidentiality and adherence.
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy